Our Bureau

Hyderabad, Dec. 2

THE President of Indian Pharmaceutical Congress, Mr V.C. Nannapaneni, has said India should gear up to exploit the emerging opportunities in contract research and clinical trials.

Addressing the 57th IPC meet here on Friday, he said many global clinical research players were favouring India as their preferred destination since the Indian scientific and technical skills match the best resources in the world. In this context, he welcomed measures of the Indian Government towards release of Indian Good Clinical Practices (GCP) and the recently revised Schedule Y and amendments carried out to the Patents Act.

"The boom in the CRO (Contract Research Organisation) segment has also brought with it the need for suitable protocols and guidelines for conducting clinical research. The need to be accepted as a reliable source for clinical research services is gaining ground in the country," Mr Nannapaneni said.

As per some estimates, the Indian clinical research market is between $100 million and $300 million, which is only a fraction of the estimated global clinical research market size of about $10 billion, the IPC President said.

"There is an immediate need to acquaint the pharmacy students in GLP, GCP, validations, analytical techniques, innovations in pharmaceutical formulation technology, clinical research, bio-equivalence studies, intellectual property rights (IPRs), quality management, regulatory management, discovery research, personality development, communication skills and shop-floor relations," Mr Nannapaneni said.

(This article was published in the Business Line print edition dated December 3, 2005)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.